- Raytheon Technologies delivered strong Q1 2022 results amid a supplies shortage, travel recovery, and Russian sanctions.
- These uncertainties are expected to persist, and the company has lowered its sales guidance to $67.75 - $68.75 billion and its organic growth rate by 1%.
- The stock now trades at full valuation compared to its own history and at a sizable premium compared to its peers.
- Considering the risk and the lack of meaningful margin of safety, my final verdict is a holding rating.
For further details see:
Raytheon Technologies: Healthy Fundamentals But Fully Valued